Heredopathia atactica polyneuritiformis is a rare genetic disease in which the body cannot properly break down a dietary fat called phytanic acid. Because of a missing or faulty enzyme (phytanoyl-CoA hydroxylase, encoded by PHYH, or, less commonly, problems with the peroxisomal targeting receptor PEX7), phytanic acid builds up in blood and tissues. Over time, this build-up can injure nerves, the retina, the skin, the inner ear, and the heart. Common problems are poor balance (ataxia), numbness or weakness (neuropathy), night blindness and retinitis pigmentosa, scaly skin (ichthyosis), loss of smell (anosmia), hearing loss, and sometimes heart rhythm problems. The core treatment is strict, lifelong restriction of phytanic-acid–rich foods (mainly ruminant meats, full-fat dairy, and certain fish) and, when levels are high or symptoms flare, plasmapheresis to rapidly lower phytanic acid. Early diagnosis and a careful diet can improve many symptoms and may slow others. NCBI+1National Organization for Rare DisordersPubMed
Heredopathia atactica polyneuritiformis is a rare inherited disease. It happens when the body cannot break down a special fat called phytanic acid. This fat then builds up in blood and tissues. The build-up slowly harms nerves, eyes, skin, ears, and sometimes the heart. People can get poor night vision, loss of smell, balance trouble, weak or numb feet and hands, dry scaly skin, and sometimes hearing loss or heart rhythm problems. The condition is passed in families in an autosomal recessive way. In most adults, changes (variants) in the PHYH gene or in PEX7 cause the problem by blocking a step called α-oxidation in peroxisomes (tiny parts of cells that process fats). A diet low in phytanic acid and, if needed, plasma exchange can lower levels and improve symptoms. NCBI+1Oxford AcademicPubMed
Other names
This disease has several names used in books and clinics. The historic name is heredopathia atactica polyneuritiformis. Today most people say Refsum disease or adult Refsum disease (ARD). Some call it phytanic acid storage disease or phytanic acid oxidase deficiency. When caused by PHYH enzyme failure it may be labeled phytanoyl-CoA hydroxylase deficiency. When due to the peroxisomal receptor PEX7, some reports say PEX7-related Refsum disease. There is also an infantile Refsum disease (IRD) within the Zellweger spectrum disorders, which is different and more severe in early life. Older medical papers sometimes shorten the name to HAP. JAMA NetworkNCBIgeneskin.org
Types
1) Classic (adult) Refsum disease (ARD).
This form usually appears from the teens to mid-adulthood. It is most often due to a defect in the PHYH gene (phytanoyl-CoA hydroxylase), which stops the body from starting the α-oxidation of phytanic acid. Some families have PEX7 variants that block peroxisomal import of the enzyme. Symptoms grow slowly and may improve when phytanic acid levels fall through diet or plasma exchange. Vision problems, smell loss, neuropathy, ataxia, ichthyosis, and hearing loss are common. NCBI+1
2) PEX7-related adult Refsum disease.
Here, the peroxisome “import signal” receptor PEX7 is faulty. The enzyme needed for α-oxidation cannot enter peroxisomes and cannot work. Clinical features look like classic ARD, but some biochemical markers can overlap with other peroxisomal issues. Management still focuses on lowering phytanic acid levels. NCBIPMC
3) Infantile Refsum disease (IRD).
This is part of the Zellweger spectrum (peroxisome biogenesis disorders). It begins in infancy, with more global development problems. It is genetically different from adult Refsum disease, though both involve phytanic acid build-up. Care is supportive and specialized. geneskin.org
4) Diet-responsive vs. diet-refractory clinical patterns.
Some people improve a lot when phytanic acid intake is reduced. Others need extra help (for example, plasma exchange) during sudden worsening. Worsening often follows fasting, illness, or weight loss, which release stored phytanic acid. PMCCleveland Clinic
Causes
Because this is an inherited disease, the root causes are gene changes. Many items below describe either the direct genetic causes or the usual “triggers” and conditions that raise phytanic acid levels and worsen symptoms.
-
Pathogenic variants in PHYH. This blocks phytanoyl-CoA hydroxylase and the first step of α-oxidation. Phytanic acid then accumulates. NCBIOxford Academic
-
Pathogenic variants in PEX7. This blocks peroxisomal import of enzymes with the PTS2 signal, including PHYH, so α-oxidation cannot start. NCBIPMC
-
Autosomal recessive inheritance. Two non-working copies (one from each parent) are required. Carriers are usually healthy. NCBI
-
High dietary phytanic acid intake. Foods rich in phytanic acid (dairy, beef, lamb, some fish) raise blood levels and drive symptoms. PubMedDARE
-
Fasting or rapid weight loss. Stored phytanic acid is released from fat, levels spike, and symptoms worsen quickly. PMC
-
Severe illness, surgery, or other physical stress. These states increase catabolism and can sharply raise phytanic acid levels, triggering weakness or arrhythmias. Cleveland Clinic
-
Poor diet planning in known patients. Without a low-phytanic acid diet, ongoing exposure sustains high levels and nerve and eye injury. Medscape
-
Unrecognized PEX7-related peroxisomal dysfunction. This can delay diagnosis and allow long exposure to high phytanic acid levels. NCBI
-
Missense variants that reduce enzyme activity. Some variants leave a little activity; disease still occurs if the net activity is too low. NCBI
-
Nonsense or frameshift variants. These can abolish enzyme production, causing earlier or more severe disease. NCBI
-
Splice-site variants. Abnormal RNA splicing can severely limit enzyme levels and function. NCBI
-
Large gene deletions/duplications. These structural changes in PHYH or PEX7 can fully remove function. NCBI
-
Founder variants in certain populations. Some groups have higher rates from shared ancestry, increasing risk in offspring when both parents carry a variant. (Inference consistent with rare-disease genetics.) NCBI
-
Lack of newborn or early screening. Without testing, years of phytanic acid exposure occur before diet is adjusted. (Clinical inference supported by natural history.) Medscape
-
Coexisting peroxisomal stressors. Other peroxisomal defects can add to the inability to process branched-chain fatty acids. PMC
-
Ineffective fat metabolism during illness. Catabolic states mobilize fats, including phytanic acid, making symptoms flare. PMC
-
Low awareness in primary care. Rarity causes diagnostic delay; ongoing exposure to phytanic acid continues the damage. (Clinical inference; see overviews.) National Organization for Rare Disorders
-
Inadequate monitoring of levels. Without checking phytanic acid and adjusting diet, levels may quietly rise again. Medscape
-
Poor access to plasma exchange during crises. When diet alone cannot lower levels quickly, symptoms can progress. PMCThe Lancet
-
Genetic chance in families with consanguinity or small gene pools. Increases the odds that both parents carry the same rare variant. (General genetic principle; ARD literature supports autosomal recessive inheritance.) NCBI
Symptoms
-
Night blindness. Seeing in low light becomes hard early in the disease, due to a rod-predominant retinitis pigmentosa-like process. NCBIGenetic Eye Diseases Database
-
Tunnel vision and field loss. Side vision shrinks over time; people bump into objects or need more light to navigate. Genetic Eye Diseases Database
-
Loss of smell (anosmia). Many patients cannot smell; they may notice food has “no smell.” Orpha
-
Poor balance and clumsy walking (ataxia). The cerebellum and sensory nerves do not send clear signals, so standing and walking feel unstable. PubMed
-
Tingling, numbness, or burning in feet and hands. This is a length-dependent peripheral neuropathy. It often starts in the toes and moves up. NCBI
-
Weakness, especially in the legs. Climbing stairs or getting up from chairs may be hard. NCBI
-
Loss of reflexes. The doctor may not find ankle or knee jerks because of nerve damage. NCBI
-
Dry, scaly skin (ichthyosis). The skin looks and feels dry with fine, plate-like scales. PubMed
-
Hearing loss. High-pitch sounds fade first; hearing aids may help. NCBI
-
Heart rhythm problems. Irregular beats or palpitations can happen, and rarely can be dangerous if levels are high. PubMedCleveland Clinic
-
Cataracts. The lens of the eye becomes cloudy, reducing clarity and contrast. Orpha
-
Macular and optic nerve changes. Central vision can drop as the macula degenerates; optic atrophy can occur later. Genetic Eye Diseases Database
-
Pupil response problems and nystagmus. Pupils may react poorly to light; some have involuntary eye movements. Genetic Eye Diseases Database
-
Fatigue and exercise intolerance. Moving with weak, numb legs is tiring; fear of falls increases fatigue. (Common clinical report in overviews.) National Organization for Rare Disorders
-
Bone or joint differences. Some people have skeletal anomalies from childhood, such as unusual bone growth at the ends of fingers or toes. PubMed
Diagnostic tests
A) Physical examination
-
General neurologic exam. The doctor checks power, tone, and reflexes. Weakness and absent ankle jerks point to polyneuropathy. This helps decide which nerves are affected. NCBI
-
Sensory exam. Testing light touch, pinprick, vibration, and position sense shows distal loss (feet and hands). This confirms sensory nerve damage and guides further tests. NCBI
-
Skin exam. The doctor looks for ichthyosis (dry, scaly skin). Seeing this pattern supports a systemic lipid storage problem. PubMed
-
Cardiac exam and vital signs. Irregular pulse or low blood pressure on standing may suggest autonomic involvement or arrhythmia risk when levels are high. This triggers ECG monitoring. PubMed
-
Eye exam with an ophthalmoscope. The retina may show pigment changes like retinitis pigmentosa; the optic nerve can look pale. This helps link vision complaints to a known pattern. Genetic Eye Diseases Database
B) Manual (bedside) tests
-
Romberg test. Standing with feet together and eyes closed checks balance. Swaying or falling suggests sensory ataxia from neuropathy. It is quick and needs no machines.
-
Tandem gait. Heel-to-toe walking tests cerebellar and sensory pathways. Wobbling or stepping off the line points to ataxia.
-
128-Hz tuning fork (vibration sense). The fork is placed on toes and ankles. Weak or absent vibration sense confirms large-fiber sensory loss typical in Refsum neuropathy.
-
Bedside smell test. Simple smell identification (coffee, soap) checks anosmia. Loss of smell is very common and fits the disease pattern. Orpha
-
Bedside hearing checks (Rinne/Weber). These quick tests screen for hearing loss and guide formal audiology if abnormal. NCBI
C) Laboratory and pathological tests
-
Plasma phytanic acid level. This is the key test. A clearly high level confirms the biochemical problem causing symptoms. Levels guide treatment and diet changes. PubMedNational Organization for Rare Disorders
-
Plasma pristanic acid and very-long-chain fatty acids (VLCFAs). In classic adult Refsum disease, phytanic acid is high, while other markers may be normal; patterns help separate adult Refsum from broader peroxisomal disorders. NCBI
-
Genetic testing for PHYH and PEX7. Finding two disease-causing variants confirms the exact cause and helps with family counseling. It also ends diagnostic delay. NCBI
-
Peroxisomal enzyme assays (specialized). In expert labs, measuring α-oxidation steps or peroxisomal functions can support the diagnosis in unclear cases. Oxford Academic
-
Basic labs (liver, kidney, lipids, glucose). These look for other problems and ensure diet and treatments are safe. They do not diagnose Refsum by themselves but are part of whole-patient care. (Clinical practice supported by reviews.) Medscape
-
Skin biopsy (if ichthyosis needs clarification). Pathology can show changes seen in ichthyosis linked to the disease, but it is optional if clinical signs are clear. ScienceDirect
D) Electrodiagnostic and electrophysiology tests
-
Nerve conduction studies (NCS). Electrodes test how fast and how strongly nerves conduct signals. In Refsum disease, a demyelinating sensorimotor polyneuropathy is typical (slow speeds, low amplitudes). This explains numbness and weakness. NCBI
-
Electromyography (EMG). A tiny needle listens to muscles. It helps separate nerve from muscle problems and tracks progression or recovery with treatment. NCBI
-
Electroretinogram (ERG). This measures the retina’s response to light. Rod responses are usually reduced, matching night blindness; it documents the retinal part of the disease. Genetic Eye Diseases Database
-
Electrocardiogram (ECG) ± Holter monitor. These record heart rhythm. They detect arrhythmias, which can appear when phytanic acid is high or during stress or fasting. If abnormal, urgent treatment to lower levels is needed. PubMedCleveland Clinic
-
Brainstem auditory evoked responses (optional). These look at how sound signals travel to the brain. Abnormal results support hearing pathway involvement seen in Refsum disease. (Consistent with neurologic involvement in overviews.) NCBI
E) Imaging tests
-
Retinal photography and optical coherence tomography (OCT). Photos show pigment changes; OCT shows the layers of the retina and macula damage. This explains vision loss and helps monitor change over time. Genetic Eye Diseases Database
-
Brain MRI (especially cerebellum). MRI can be normal, but sometimes shows cerebellar or white-matter changes that match ataxia or neuropathy. Imaging also rules out other causes of imbalance. (Supported by clinical series and reviews.) Medscape
-
Skeletal X-rays (selected cases). Some patients have bone end (epiphyseal) changes; X-rays can document these when suspected from exam. PubMed
-
Echocardiogram (if indicated). Ultrasound of the heart checks pumping and structure when ECG or symptoms suggest cardiac involvement. This helps prevent complications. PubMed
Non-pharmacological treatments
Important: Diet low in phytanic acid is foundational and continues alongside everything below. DARE
Physiotherapy & Rehabilitation
-
Balance and gait training. A physical therapist teaches wide-base stance, weight-shift drills, and safe turning. Purpose: reduce falls. Mechanism: repeated practice builds cerebellar compensation and strengthens postural muscles. Benefits: steadier walking, fewer injuries.
-
Strength training for lower limbs. Simple, supervised exercises (sit-to-stand, step-ups, resistance bands). Purpose: improve push-off and knee control. Mechanism: hypertrophy and neuromuscular recruitment. Benefits: better endurance, safer stairs.
-
Core stability work. Bridges, side planks, and trunk control drills. Purpose: stabilize the trunk for smoother limb movement. Mechanism: improves proximal stability so distal control improves. Benefits: less sway, easier transfers.
-
Stretching program. Daily calf, hamstring, and hand flexor stretches. Purpose: maintain range, prevent contractures from neuropathy or reduced activity. Mechanism: viscoelastic muscle-tendon adaptation. Benefits: smoother gait, less stiffness.
-
Task-specific gait practice with cues. Walking to metronome or visual markers. Purpose: improve rhythm and foot placement. Mechanism: external cueing bypasses impaired internal timing. Benefits: more consistent pace, fewer stumbles.
-
Vestibular rehabilitation. Gaze stabilization and habituation drills for patients with dizziness. Purpose: reduce imbalance and visual blurring. Mechanism: central adaptation of vestibulo-ocular reflexes. Benefits: steadier head turns, less vertigo.
-
Assistive device training. Fitting of cane, trekking poles, or walker; practice safe use. Purpose: immediate safety. Mechanism: increases base of support and tactile feedback. Benefits: fewer falls, confidence.
-
Functional electrical stimulation (FES) for foot drop (case-by-case). Purpose: improve ground clearance. Mechanism: timed peroneal nerve stimulation. Benefits: fewer trips, faster gait. (Use with clinician oversight.)
-
Hand therapy for fine motor control. Grip and pinch exercises, adaptive utensils. Purpose: improve daily tasks. Mechanism: repetitive motor learning. Benefits: easier writing/eating, independence.
-
Energy-conservation pacing. Break tasks into chunks, rest before fatigue. Purpose: manage neuropathic fatigue. Mechanism: balances workload with nerve recovery. Benefits: more stable function across the day.
-
Spasticity/tone management positioning. Proper seating, ankle-foot orthoses when indicated. Purpose: align joints, reduce falls. Mechanism: biomechanical support. Benefits: safer mobility, less pain.
-
Aquatic therapy. Water buoyancy reduces load while training gait and balance. Purpose: low-impact conditioning. Mechanism: hydrostatic resistance and sensory input. Benefits: endurance without joint strain.
-
Falls-proofing the home. Remove rugs, add grab bars, improve lighting. Purpose: injury prevention. Mechanism: reduces environmental hazards. Benefits: fewer emergency visits.
-
Occupational therapy (ADL training). Task modifications, kitchen/bathroom safety, work simplification. Purpose: keep independence. Mechanism: ergonomic redesign. Benefits: safer, faster self-care.
-
Low-vision rehabilitation. Orientation-and-mobility skills, magnifiers, contrast enhancement. Purpose: compensate for retinitis pigmentosa. Mechanism: assistive optics and training. Benefits: reading/navigation independence. Foundation Fighting Blindness
Mind-Body & Psychosocial Care
-
Cognitive-behavioral strategies for chronic symptoms. Purpose: reduce distress, improve coping. Mechanism: reframing thoughts about symptoms. Benefits: better adherence to diet and rehab.
-
Mindfulness and paced breathing. Purpose: calm the nervous system, improve pain tolerance. Mechanism: parasympathetic activation. Benefits: lower anxiety, steadier focus in therapy.
-
Peer support groups. Purpose: share diet tips and lived experience. Mechanism: social learning and accountability. Benefits: sustained adherence. (Global DARE resources can help.) DARE
-
Sleep hygiene program. Purpose: support nerve recovery and mood. Mechanism: circadian stabilization. Benefits: energy and concentration.
-
Vocational counseling. Purpose: align work tasks with physical abilities. Mechanism: job modification and pacing. Benefits: maintain employment.
Educational, Genetic & Diet-Centered Care
-
Dietitian-led phytanic-acid-restricted diet training. Detailed food lists and label reading. Purpose: lower body burden. Mechanism: cut intake from ruminant meats, full-fat dairy, and certain fish. Benefits: can reverse or improve neuropathy, ichthyosis, and ataxia. DAREWiley Online LibraryPubMed
-
Emergency-flare plan. Recognize triggers (fasting, rapid weight loss) and seek care for plasmapheresis when needed. Purpose: prevent acute spikes. Mechanism: rapid removal of circulating phytanic acid. Benefits: faster control of arrhythmias/weakness. Karger
-
Genetic counseling for patients and family. Purpose: clarify inheritance (autosomal recessive), carrier testing, and reproductive options. Mechanism: risk assessment and education. Benefits: informed decisions. NCBI
-
Medication safety education. Avoid drugs that may worsen arrhythmias or interact with neuropathy meds; coordinate with cardiology. Purpose: reduce iatrogenic risks. Mechanism: proactive reconciliation. Benefits: safer care.
-
Vision/hearing rehabilitation planning. Early referral for low-vision aids and hearing amplification. Purpose: preserve function as sensory loss progresses. Mechanism: assistive tech and training. Benefits: quality of life. Foundation Fighting Blindness
Drug treatments
Safety note: Doses below are typical adult ranges and must be individualized by a clinician considering kidney, liver, heart rhythm status, and drug interactions—especially because some patients have arrhythmias. These medicines manage symptoms; they do not replace the low-phytanic-acid diet or plasmapheresis when indicated. Karger
-
Gabapentin (anticonvulsant/neuropathic pain).
Dose/time: Start 100–300 mg at night, titrate to 900–3600 mg/day in 3 doses.
Purpose: Reduce burning, tingling, and shooting pain from neuropathy.
Mechanism: Binds α2δ subunit of voltage-gated calcium channels, dampening hyperexcitable neurons.
Side effects: Drowsiness, dizziness, edema; adjust in renal disease. -
Pregabalin (neuropathic analgesic).
Dose: 50–75 mg twice daily; up to 150–300 mg twice daily.
Purpose: Neuropathic pain and sleep.
Mechanism: Similar α2δ binding; reduces synaptic glutamate/substance P.
Side effects: Dizziness, weight gain, edema; adjust for kidneys. -
Duloxetine (SNRI).
Dose: 30 mg daily ×1–2 weeks, then 60 mg daily.
Purpose: Neuropathic pain and mood.
Mechanism: Serotonin/norepinephrine reuptake inhibition; descending pain modulation.
Side effects: Nausea, dry mouth, blood pressure changes; avoid in severe hepatic disease. -
Amitriptyline (TCA).
Dose: 10–25 mg nightly; titrate to 50–100 mg if tolerated.
Purpose: Night pain, sleep.
Mechanism: Serotonin/norepinephrine reuptake blockade, anticholinergic effects.
Side effects: Dry mouth, constipation, QT prolongation—cardiac review is vital. -
Topical urea 10–40% (keratolytic for ichthyosis).
Use: Apply 1–2×/day.
Purpose: Reduce scaling and cracking.
Mechanism: Humectant/keratolysis softens stratum corneum.
Side effects: Stinging; avoid open wounds. (Diet improves ichthyosis too.) DARE -
Topical lactic acid 5–12% or salicylic acid 3–6% (keratolytics).
Use: 1–2×/day to scaly areas.
Purpose: Smoother skin.
Mechanism: Corneocyte desquamation.
Side effects: Irritation; dermatology guidance helpful. -
Emollients (petrolatum, ceramide creams).
Use: Multiple times daily, especially after bathing.
Purpose: Barrier repair for ichthyosis.
Mechanism: Occlusion and lipid replacement.
Side effects: Minimal. -
Omega-3 algal DHA (if used, algal-based, not fish oil).
Dose: Commonly 200–500 mg DHA/day (clinician-guided).
Purpose: General cardiometabolic support without fish-derived phytanic acid.
Mechanism: Membrane effects and inflammation modulation.
Side effects: Mild GI upset. Use dietitian guidance to avoid hidden phytanic acid. Wiley Online Library -
Acitretin (systemic retinoid, dermatology-supervised only).
Dose: Often 10–25 mg/day for severe ichthyosis (if topical therapy fails).
Purpose: Reduce severe scaling.
Mechanism: Normalizes keratinization.
Side effects: Teratogenicity, dyslipidemia, liver effects; strict specialist oversight. -
Epinephrine autoinjector (if severe fish/dairy allergy coexists).
Dose: 0.3 mg IM when anaphylaxis occurs.
Purpose/Mechanism: Emergencies only; not for Refsum itself.
Side effects: Tremor, palpitations. -
Metoprolol or other beta-blocker (cardiology-guided).
Dose: Variable; example 25–100 mg/day in divided doses.
Purpose: Rate control and symptom relief in some arrhythmias.
Mechanism: β-adrenergic blockade.
Side effects: Bradycardia, fatigue. Cardiology must supervise. Cleveland Clinic -
Amiodarone (only if specialist deems necessary).
Dose: Protocol-based loading then maintenance.
Purpose: Refractory arrhythmias.
Mechanism: Class III antiarrhythmic.
Side effects: Thyroid, pulmonary, liver toxicity; QT prolongation—specialist oversight required. -
Loop diuretic (e.g., furosemide) if heart failure present.
Dose: 20–40 mg orally, titrated.
Purpose: Symptom control of congestion.
Mechanism: Inhibits Na-K-2Cl in loop of Henle.
Side effects: Electrolyte imbalance—monitor. -
Acetylsalicylic acid (low-dose) if cardiology indicates.
Dose: 75–100 mg/day.
Purpose: Vascular risk per general cardiology practice.
Mechanism: Platelet COX-1 blockade.
Side effects: GI irritation; not routine for all patients. -
Ondansetron (for procedure-related nausea).
Dose: 4–8 mg PRN.
Purpose: Improve tolerance of apheresis or medication side effects.
Mechanism: 5-HT3 receptor blockade.
Side effects: Constipation, QT caution.
Key reminder: The most effective “treatment” remains diet and plasmapheresis when levels are high; medicines above assist symptoms but do not clear phytanic acid. KargerPubMed
Dietary molecular supplements
(Use only with clinician/dietitian guidance to avoid hidden phytanic acid; evidence ranges from supportive to limited.)
-
Medium-chain triglyceride (MCT) oil.
Dose: Often 1–3 tablespoons/day as tolerated.
Function: Energy source with negligible phytanic acid.
Mechanism: Absorbed directly via portal vein; does not add phytanic load. Dietitian supervision needed. -
Algal-derived DHA (not fish oil).
Dose: 200–500 mg/day.
Function: Retinal and neural membrane support without fish-derived phytanic acid.
Mechanism: Incorporates into phospholipids. Wiley Online Library -
Vitamin E.
Dose: Often 200–400 IU/day (individualized).
Function: Antioxidant support for nerves and retina.
Mechanism: Limits lipid peroxidation. -
Vitamin D3.
Dose: Per level; e.g., 1000–2000 IU/day or repletion protocol.
Function: Bone and muscle health with reduced dairy intake.
Mechanism: Endocrine regulation of calcium/phosphate. -
B-complex (B1, B6, B12).
Dose: Standard daily amounts or targeted if low.
Function: Nerve metabolism support.
Mechanism: Cofactors in axonal energy pathways. -
Alpha-lipoic acid.
Dose: 300–600 mg/day.
Function: Adjunct for neuropathic symptoms (evidence moderate in diabetic neuropathy).
Mechanism: Antioxidant, improves nerve glucose handling. -
Coenzyme Q10.
Dose: 100–300 mg/day with food.
Function: Mitochondrial electron transport support.
Mechanism: Enhances oxidative phosphorylation. -
Magnesium (glycinate/citrate).
Dose: 200–400 mg elemental/day.
Function: Muscle cramps and sleep support.
Mechanism: Neuromuscular excitability modulation. -
Zinc (if low).
Dose: 10–25 mg elemental/day for short courses.
Function: Skin repair and immune function.
Mechanism: Enzymatic cofactor in keratinocytes. -
Probiotic (dairy-free formulation).
Dose: As per label.
Function: Gut comfort during diet changes.
Mechanism: Microbiome support; choose dairy-free to avoid phytanic acid sources.
Immunity-booster / regenerative / stem-cell drugs
There are no approved immune-booster, regenerative, or stem-cell drugs that treat Refsum disease itself. The disease mechanism is accumulation of phytanic acid from diet due to defective peroxisomal α-oxidation; current, evidence-based treatments are dietary restriction and plasmapheresis, with supportive rehab and symptom care. Experimental ideas (e.g., gene therapy for PHYH or PEX7, peroxisome-targeting strategies) remain research-stage; dosing is protocol-specific and not for routine care. If you are interested, ask a metabolic specialist about clinical trials and registries. NCBIKarger
Safer, evidence-aligned “six ways” to pursue regeneration/immune health within standard care:
-
Vaccinations up to date (flu, COVID-19, pneumococcal as indicated) to reduce systemic stressors.
-
Supervised resistance training to stimulate neuro-muscular plasticity.
-
Optimize sleep and vitamin D for immune support.
-
Cardiac risk control (BP, lipids) to protect perfusion of nerves and retina.
-
Treat comorbid deficiencies (B12, iron, folate) that can worsen neuropathy.
-
Enroll in research when available; it advances the field without unsafe self-experimentation.
Procedures / surgeries
-
Therapeutic plasmapheresis (plasma exchange).
Procedure: Blood is circulated through a machine; plasma is removed and replaced (e.g., with albumin).
Why done: Rapidly lowers very high phytanic acid during flares or when symptoms like arrhythmia or severe weakness worsen. Diet continues afterward. Karger -
Implantable pacemaker or defibrillator (ICD).
Procedure: Device placed under skin with leads to heart.
Why done: For significant conduction disease or life-threatening arrhythmias to prevent fainting or sudden death. Cardiology decides candidacy. Cleveland Clinic -
Cataract extraction.
Procedure: Clouded lens removed and replaced with an artificial lens.
Why done: Improves vision when cataracts are visually significant (common in Refsum). Cleveland Clinic -
Tendon-release/orthopedic procedures (select cases).
Procedure: Correct contractures or deformities impairing function.
Why done: Improve mobility and hygiene when conservative care fails. -
Cochlear implant or advanced hearing devices.
Procedure: Electronic device implanted to stimulate the auditory nerve.
Why done: For severe sensorineural hearing loss not corrected by hearing aids, to restore access to sound.
Prevention & self-management tips
-
Strict, lifelong low-phytanic-acid diet. This is the single most important prevention step. DARE
-
Avoid fasting or rapid weight loss. These can release stored phytanic acid from fat into the blood. Karger
-
Plan for travel and social events. Carry safe snacks and an “avoid list.”
-
Work with a dietitian who knows Refsum; review labels regularly. DARE
-
Regular monitoring of blood phytanic acid levels and heart rhythm. NCBI
-
Protect vision and hearing (sunglasses in bright light; noise protection). Foundation Fighting Blindness
-
Fall-proof your home and use aids if recommended.
-
Maintain an emergency card stating the diagnosis and diet needs.
-
Keep vaccinations current to limit systemic stressors.
-
Family genetic counseling for carrier testing and planning. NCBI
When to see a doctor
-
Right away / urgent: New or worsening chest pain, palpitations, fainting, fast or irregular heartbeat; sudden weakness, severely worsening balance, or vision loss; severe dehydration or rapid weight loss; any surgical-level pain or injury from a fall. (Cardiac problems are part of the disease and can be serious.) Cleveland Clinic
-
Soon (within days): More numbness, burning pain not controlled, new skin cracking/bleeding, new hearing changes, or if you accidentally eat high-phytanic foods.
-
Routine: Regular follow-ups with metabolic specialist, dietitian, neurologist, cardiologist, dermatologist, ophthalmologist, and audiologist to update diet, track labs, and adjust rehab or devices. NCBI
What to eat and what to avoid
-
Avoid: Beef, lamb/mutton, goat, and products made from them (including tallow). These are high in phytanic acid. Wiley Online Library
-
Avoid: Full-fat dairy (whole milk, cream, butter, cheese, yogurt) from cow, sheep, goat. DARE
-
Avoid: Several fish (especially cod liver oil and certain marine fish) that carry phytanic acid—follow disease-specific lists from your clinic/dietitian. Wiley Online Library
-
Prefer: Fruits, vegetables, grains, legumes, and lean, non-ruminant proteins (e.g., poultry, many plant proteins). Work with a dietitian to tailor choices. DARE
-
Use: Plant oils and MCT oil as advised for calories and satiety.
-
Check labels: watch for hidden dairy fats (whey, casein, butterfat).
-
Choose dairy-free fortified alternatives for calcium/vitamin D.
-
Hydrate steadily; avoid long fasts or crash diets. Karger
-
Plan protein: mix plant proteins to meet needs without ruminant sources. DARE
-
Keep a personal food list reviewed by your clinic, since local foods vary and phytanic acid content differs among products. Wiley Online Library
Frequently asked questions (FAQs)
1) Is “heredopathia atactica polyneuritiformis” the same as Refsum disease?
Yes. It is the historic name for adult Refsum disease, a phytanic-acid storage disorder. Wikipedia
2) What causes it?
Inherited variants in PHYH (most cases) or PEX7 (fewer cases) impair α-oxidation of phytanic acid in peroxisomes. NCBI
3) Where does phytanic acid come from?
From diet, mainly ruminant meat, full-fat dairy, and some fish. The body does not make it. National Organization for Rare Disorders
4) What symptoms should I watch for?
Balance problems, numbness/tingling, night blindness/retinitis pigmentosa, ichthyosis, anosmia, hearing loss, and heart rhythm problems. NCBICleveland Clinic
5) Can diet really improve symptoms?
Yes. Strict low-phytanic-acid diet can improve neuropathy, ataxia, and ichthyosis and may slow vision/hearing decline. PubMedDARE
6) What is plasmapheresis and when is it used?
A machine removes plasma and rapidly lowers phytanic acid; used during flares or when levels are very high and symptoms worsen. Karger
7) Are there medicines that fix the enzyme problem?
No. Medicines relieve symptoms; diet and plasmapheresis target phytanic acid burden. Gene-based therapies are research-stage. NCBI
8) Is fasting dangerous?
Yes, it can release stored phytanic acid from fat, raising blood levels; avoid fasting and rapid weight loss. Karger
9) How is the diagnosis made?
By elevated phytanic acid in blood, clinical features, and genetic testing of PHYH/PEX7. Doctors may also check nerve studies, eye exams, heart tests, and skin findings. NCBI+1
10) What eye problems occur?
Retinitis pigmentosa with night blindness and field loss; cataracts may also occur. Low-vision rehab and cataract surgery can help. Foundation Fighting BlindnessCleveland Clinic
11) Is pregnancy possible with this disease?
Yes, but diet becomes even more important, and medications must be reviewed. Pre-pregnancy genetic counseling helps with planning. NCBI
12) Do fish oils help?
Avoid standard fish oils due to possible phytanic acid. If omega-3s are used, choose algal DHA after consulting your team. Wiley Online Library
13) Can children have it?
Yes; it is genetic. Presentation varies. Diet and, if needed, plasmapheresis are used in pediatric care under specialists. PubMed
14) Will I need surgery?
Only for specific issues like cataracts, severe arrhythmias (devices), or contractures; many people do not need surgery. Cleveland Clinic
15) What kind of team should I have?
A metabolic specialist, neurologist, cardiologist, dermatologist, ophthalmologist, audiologist, dietitian, and rehab therapists. This team approach gives the best results. NCBI
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 09, 2025.



